A multi-centre 3-arm randomized phase II trial of BIBF 1120 versus BIBW 2992 versus sequential administration of BIBF 1120 and BIBW 2992 in patients with hormone-resistant prostate cancer

Phase 1

• Conditions: Chemo-naive hormone refractory prostate cancer

• Registration Number: EUCTR2005-005249-21-GB
• Lead Sponsor: Boehringer Ingelheim Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-01-20
• Study Completion: 2008-12-19
• Last Update Posted: 25 November 2019

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Not specified
• Target Recruitment: 105

Inclusion Criteria

•Age >18 years.
•Signed informed consent.
•Able to comply with protocol requirements.
•Histologically, cytologically or biochemically documented adenocarcinoma of the prostate, clinically refractory or resistant to hormone therapy, as documented by progression following at least one hormonal therapy, which must include orchidectomy or gonadotropin releasing hormone agonist (GnRHa).
•Progressive Disease (PD) is defined as a minimum of three consecutive serum PSA measurements obtained at least 7 days apart within the previous 3 months of start of trial, which document progressively increasing values. Patients with progression of measurable disease (RECIST) or progression of bone disease must also fit the criterion for PSA progression.
•Patients must have documented progression (as defined above) following anti-androgen withdrawal of 4 weeks duration for flutamide and 6 weeks for bicalutamide or nilutamide. For a patient who has withdrawn from anti-androgen therapy less than 6 months prior to inclusion in trial one of the following criteria is also required:
•Following the completion of the anti-androgen withdrawal period one PSA higher than the last pre-withdrawal PSA.
Or
•Following the completion of the anti-androgen withdrawal period if the PSA value has decreased, he can still qualify if 2 increases in PSA are documented after the post- withdrawal nadir.
•PSA > 5ng/mL.
•Life expectancy of at least 12 weeks.
•ECOG performance status 0-1
•Stable analgesia requirements.
•Adequate hepatic function: total bilirubin < 26µmol/L, ALT and/or AST < 1.5x upper limit of normal (ULN).
•Adequate renal function: serum creatinine =1.5 x ULN.
•INR Prothrombin time (PT) and partial thromboplastin time (PTT) <1.5 upper limit of normal.
•Absolute neutrophil count (ANC) = 1.5 x109/l, Platelets =100 x 109/l.
•Haemoglobin = 9.0 g/dl.
•LVEF =50 % on MUGA scan or echocardiogram.
•Castrate testosterone level [< 20ng/dl or <0.69nM (nM/L x 28.8 = ng/dl)], which must be maintained during the duration of the trial by orchidectomy or medical castration.
•Patient on oral or intravenous bisphosphonates are allowed to enter the trial as long as they have been on bisphosphonates for a minimum of 3 months.

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

•Prior treatment with inhibitors of EGFR, HER 2 and/or VEGF receptors.
•Prior treatment with cytotoxic chemotherapy.
•Known hypersensitivity to the trial drugs or their excipients.
•Systemic corticosteroids 28 days before screening (inhaled corticosteroids prescribed for bronchospasm are allowed). Patients on long-term stable-dose steroids for concurrent illness are not excluded.
•Treatment with any investigational drug within 28 days of trial onset.
•History of other malignancies which could affect compliance with the protocol or interpretation of results within 5-years. Patients with adequately treated basal or squamous cell skin cancer are generally eligible.
•Serious illness or concomitant non-oncological disease such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with trial participation or trial drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the trial.
•Major injuries and/or surgery within 4 weeks of trial onset or bone fracture and planned surgical procedures during the trial period.
•Significant cardiovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of infarction within past 9 months, congestive heart failure > NYHA II).
•History of haemorrhagic or thrombotic event in the past 12 months. Known inherited predisposition to bleeds or to thrombosis.
•Patient with history or clinical evidence of CNS disease or brain metastases.
•Patients with symptoms of impending or established spinal cord compression.
•Gastrointestinal disorders or abnormalities that would inhibit absorption of the trial drug.
•Patients who require full-dose anticoagulation.
•Radio- or immunotherapy within the past four weeks prior to treatment with the trial drug.
•Patients unable to comply with the protocol.
•Active alcohol or drug abuse.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: To estimate and compare the 12-week progression-free rate of BIBF 1120, BIBW 2992 or sequential administration of BIBF 1120 and BIBW 2992 in patients with HRPC as determined by radiographic, bone and PSA criteria.;Secondary Objective: To evaluate additional efficacy related endpoints (e.g. PSA response/progression, duration of PSA response, RECIST tumor progression rate, time to progression, overall objective response, overall survival) and safety related endpoints (e.g. incidence and intensity of adverse events, changes in safety laboratory parameters);Primary end point(s): Progression-free rate (defined by a composite endpoint of absence of PSA, bone metastasis and RECIST progression) after 12 weeks of treatment in each of the treatment arms